BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 239 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $321,644 | +21.7% | 52,046 | 0.0% | 0.02% | +19.0% |
| Q1 2024 | $264,394 | -15.2% | 52,046 | 0.0% | 0.02% | -12.5% |
| Q4 2023 | $311,756 | -15.4% | 52,046 | 0.0% | 0.02% | 0.0% |
| Q3 2023 | $368,486 | +23.2% | 52,046 | +22.5% | 0.02% | +14.3% |
| Q2 2023 | $299,066 | -4.6% | 42,481 | +13.0% | 0.02% | -22.2% |
| Q1 2023 | $313,484 | +106165.8% | 37,588 | +46.1% | 0.03% | +3.8% |
| Q4 2022 | $295 | -99.9% | 25,721 | +1.2% | 0.03% | -21.2% |
| Q3 2022 | $320,000 | +6300.0% | 25,411 | +3709.7% | 0.03% | – |
| Q1 2019 | $5,000 | – | 667 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,076,924 | 27.82% |
| Prosight Management, LP | 5,000,000 | $35,200,000 | 5.27% |
| Saturn V Capital Management LP | 954,856 | $6,722,186 | 3.73% |
| ORACLE INVESTMENT MANAGEMENT INC | 555,522 | $3,910,875 | 2.88% |
| Kynam Capital Management, LP | 2,848,197 | $20,051,307 | 2.76% |
| TANG CAPITAL MANAGEMENT LLC | 2,450,000 | $17,248,000 | 2.54% |
| AlphaCentric Advisors LLC | 570,000 | $4,012,800 | 2.23% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 760,904 | $5,356,764 | 1.66% |
| Eversept Partners, LP | 2,372,113 | $16,699,676 | 1.40% |
| Avoro Capital Advisors LLC | 12,055,000 | $84,867,200 | 1.15% |